Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
暂无分享,去创建一个
S. Fox | S. Lade | N. Traficante | S. Fereday | J. Hung | Y. Chiew | A. deFazio | D. Bowtell | L. Galletta | N. Pavlakis | C. Scott | E. Swisher | T. Healy | I. McNeish | N. Zeps | R. Pearson | A. Dobrovic | M. Wakefield | D. Purdie | S. Kaufmann | I. Haviv | N. Johnson | M. Friedlander | A. Proietto | E. Sanij | D. Rischin | K. Nattress | O. Kondrashova | R. Stuart-Harris | M. Harrell | M. Oehler | K. Alsop | C. Dalrymple | J. Pyman | A. Obermair | T. Harding | L. Jackman | G. Gard | N. Pandeya | W. Murray | K. Phillips | V. Heong | P. Harnett | J. Hendley | D. Giles | A. Green | K. Harrap | J. Carter | R. Bell | L. Bowes | P. Beale | K. Nešić | P. Mamers | M. Davy | S. Braye | S. Ananda | M. Topp | G. Ho | I. Simpson | T. Jobling | S. Begbie | Giada V. Zapparoli | D. Allen | J. Krais | T. Bonaventura | B. Brown | P. Grant | M. Jones | A. Ferrier | D. Nevell | S. Valmadre | L. Edwards | C. Underhill | R. Sharma | R. Robertson | A. Crandon | D. Wyld | K. Hutt | V. Jayde | V. Billson | P. Blomfield | N. O’Callaghan | T. Manolitsas | D. Neesham | R. Houghton | K. Horwood | B. Susil | S. Baron-Hay | C. Camaris | P. Russell | E. Sumithran | N. Hacker | M. Quinn | M. Links | R. Laurie | L. Green | A. Brand | S. Hyde | T. Dodd | P. Clingan | Emma Boehm | D. Whiteman | D. Challis | A. Hadley | Elizabeth Lieschke | P. Waring | A. Martyn | D. Papadimos | I. Hammond | P. Mackenzie | F. Kirsten | B. Ranieri | G. Otton | K. Lin | M. Malt | R. McIntosh | G. Wain | J. Nicklin | O. McNally | A. Stenlake | V. Ganju | B. Young | D. Healy | Y. Leung | M. Loughrey | J. Beith | G. Robertson | K. Pittman | A. McCartney | D. Gertig | Robert Holian | P. Webb | G. Chenevix-Trench | T. Sadkowsky | A. Mellon | J. Maidens | H. Sullivan | B. Alexander | P. Ashover | S. Brown | T. Corrish | K. Martin | J. White | T. Schmidt | H. Shirley | C. Ball | C. Young | S. Viduka | H. Tran | L. Glavinas | J. Rutovitz | J. Shannon | J. Stewart | D. Bell | R. Crouch | D. Marsden | J. Grygiel | J. Hill | R. Jaworski | B. Ward | M. Cummings | L. Perrin | D. Henderson | J. Pierdes | R. Rome | M. Robbie | J. McNealage | P. Rogers | D. Johnson | L. Ng | R. Blum | M. Buck | G. A. P. D. S. S. J. K. T. N. M. A. R. T. M. P. J. K. Chenevix-Trench Green Webb Gertig Fereday Moor | S. Bilić | J. Brooks | C. Hall | A. Parker | K. ferguson | S. Moore | T. Vanden Bergh | A. Glasgow | K. Byth | J. Miller
[1] Paul Ellis,et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial , 2018, Nature Medicine.
[2] James X. Sun,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[3] E. Lander,et al. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.
[4] James X. Sun,et al. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2017, Cancer discovery.
[5] E. Swisher,et al. Overall survival in BRCA1 or RAD51C methylated vs mutated ovarian carcinoma following primary treatment with platinum chemotherapy , 2017 .
[6] E. Kohn,et al. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization , 2017, Clinical Cancer Research.
[7] D. Levine,et al. The EMSY threonine 207 phospho-site is required for EMSY-driven suppression of DNA damage repair , 2017, Oncotarget.
[8] Matthew J. Wakefield,et al. SurvivalVolume: interactive volume threshold survival graphs , 2016, J. Open Source Softw..
[9] Ignace Vergote,et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.
[10] Y. Wang,et al. The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. , 2016, Cancer research.
[11] Werner Meier,et al. Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy , 2016, Cancer.
[12] Tom Walsh,et al. Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.
[13] G. Taylor,et al. High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq , 2015, PloS one.
[14] J. O’Leary,et al. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. , 2015, Experimental cell research.
[15] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[16] Steven L Salzberg,et al. HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.
[17] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .
[18] Paul Theodor Pyl,et al. HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[19] R. Zeillinger,et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). , 2014, European journal of cancer.
[20] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.
[21] S. Fox,et al. Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts , 2014, Molecular oncology.
[22] L. Karnitz,et al. Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors* , 2014, The Journal of Biological Chemistry.
[23] Jian-Bing Fan,et al. Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status , 2014, Scientific Reports.
[24] Sheena M. Scroggins,et al. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas , 2013, Clinical Cancer Research.
[25] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[26] G. Shapiro,et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance , 2013, Proceedings of the National Academy of Sciences.
[27] C. Sander,et al. Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.
[28] G. Mills,et al. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation , 2013, Molecular oncology.
[29] J. George,et al. Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations , 2013, Clinical Cancer Research.
[30] Justine Collier,et al. DNA methylation by CcrM activates the transcription of two genes required for the division of Caulobacter crescentus , 2013, Molecular microbiology.
[31] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[32] R. Drapkin,et al. Primary culture and immortalization of human fallopian tube secretory epithelial cells , 2012, Nature Protocols.
[33] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[35] A. Ashworth,et al. Functional characterization of EMSY gene amplification in human cancers , 2011, The Journal of pathology.
[36] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[37] Graham G. Giles,et al. Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer , 2010, Cancer Prevention Research.
[38] J. Herman,et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[40] Carlos Caldas,et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.
[41] M. Robinson,et al. A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.
[42] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[43] Rochelle L. Garcia,et al. Molecular Cancer Methylation and Protein Expression of Dna Repair Genes: Association with Chemotherapy Exposure and Survival in Sporadic Ovarian and Peritoneal Carcinomas , 2022 .
[44] Alan Ashworth,et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] F. Couch,et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.
[46] Jorge S. Reis-Filho,et al. Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.
[47] Maurice B Loughrey,et al. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype , 2008, Breast Cancer Research.
[48] R. L. Baldwin,et al. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. , 2006, Gynecologic oncology.
[49] Luke Hughes-Davies,et al. EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer , 2003, Cell.
[50] J. Rice,et al. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. , 2000, Nucleic acids research.
[51] J. Herman,et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.
[52] G. Chenevix-Trench,et al. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. , 2000, Carcinogenesis.
[53] Chun-Fang Xu,et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.
[54] J. Rice,et al. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells , 1998, Oncogene.
[55] A. Dobrovic,et al. Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.
[56] A. Godwin,et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Monks,et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer , 1990, International journal of cancer.
[58] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[59] F. Couch,et al. Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma , 2009 .